Categories

January 23, 2021

My News on Point

Daily News Update From Top News Blog Around The World | Your News on The Go

Vice President Yemi Osinbajo has welcomed efforts by a team of Nigerian professors and scientists investigating the effectiveness of, and roles that Ivermectin drug can play in the treatment of the Coronavirus disease.

The team, which is composed of Nigerian scholars at home and abroad, has also submitted their report on the usefulness of the drug to the World Health Organisation which has already appointed a Peer Review expert from the United Kingdom.

Speaking Tuesday while being briefed on the report by a team of scientists led by Femi Babalola, the Principal investigator, and Chris Bode, the Chief Medical Director of LUTH, the Vice President expressed excitement that Nigeria and Nigerians “are at the cutting edge of scientific research into the COVID-19 treatment.”

According to him, “we have an opportunity here and I am so fascinated to hear this drug has been used in the treatment of River Blindness in this country.”

While commending the efforts of the team, Mr Osinbajo added that with the report, Nigeria is at an advantage both in knowledge and availability of the drug, especially since Ivermectin has been found useful not only in the treatment of COVID-19, but also as a prophylactic medication.

He disclosed that the Federal Government will explore further ways to support the research for the benefit of Nigerians and humanity generally, while also advancing the effective funding of scientific research in the country.

Members of the group named IVERCOVID Research Group are the Principal Investigator, Femi Babalola, an Ophthalmologist and surgeon; the Chief Medical Director of LUTH, Chris Bode; the Chairman of the Medical Advisory Council at LUTH, Lanre Adeyemo; a US-based Clinical Pharmacologist, Adesuyi Ajayi; two project virologists: S.A Omilabu and Olumuyiwa Salu; and also the Project Coordinator, Felix Alakaloko.

Both Mr Babalola and the CMD, LUTH commended the Buhari Presidency for encouraging the research and thanked the Vice President for his personal role and support.

The report is titled, “A randomised controlled trial for the repurposing of Ivermectin in the management of COVID-19,” and highlights are discussed below:

The research, carried out in the Lagos University Teaching Hospital (LUTH) was undertaken following the report of a 5,000-fold reduction in viral load by Australian workers with in-vitro use of Ivermectin on COVID-19 in culture.

The PI has worked extensively with Ivermectin on the Onchocerciasis-River Blindness control programme, through which many Nigerians have used Ivermectin.

FINDINGS

The study revealed that the mechanism of action of Ivermectin, include “Inhibiting viral entry into cells nucleus; and “Direct suppression of viral RNA load of SARS CoV 2,” among others.

Dangote adbanner 728x90_2 (1)

Ivermectin is orally absorbed with higher absorption as a solution better than tablets, and “The Mean Residence Time” (MRT) is 3.4 days. This informs the suggested frequency of dosing, i.e. twice a week.

Vice President Yemi Osinbajo, SAN, speaking yesterday while being briefed on the report by a team of scientists. (Photo Credit: Tolani Alli)
Vice President Yemi Osinbajo, SAN, speaking yesterday while being briefed on the report by a team of scientists. (Photo Credit: Tolani Alli)

The research’s Null hypothesis noted that: “Safe doses of Ivermectin are not useful in the treatment of patients with virology proven COVD-19 disease, does not lower viral load, and does not shorten time to negativity, neither does it cause improvement in clinical parameters when compared to Lopinavir/Ritonavir/Placebo.”

But its Alternative Hypothesis revealed that, “Safe doses of Ivermectin are useful in the treatment of patients with virology proven COVID-19 disease, lowering viral load, shortening time to negativity, and causing improvement in clinical parameters when compared with Lopinavir/Ritonavir/Placebo.”

RESULTS

In its results so far, the Study noted that the randomisation was effective based on distribution of age, sex and some clinical presentation at baseline such as cough and fever.

The overall results showed that the “Days-To-Negative (DTN) reduced by 3.8 days overall. While a few patients are negative by day two, 50 per cent are negative by day 5.”

The study indicated that Clinical trials of Ivermectin have been carried out in at least 21 countries worldwide, including Nigeria. It referenced the “Meta-analysis of clinical trials of Ivermectin to treat COVID-19 infection” by Dr. Andrew Hill, Department of Pharmacology, University of Liverpool, UK.

Highlighting the practical applications, the Study proposed that “Ivermectin should be considered for adoption into the uniform treatment guidelines of COVID- 19 in Nigeria,” noting the “potential use of ivermectin as prophylaxis Pending the rollout of vaccination programs or alongside it.”

However, the Study emphasized that Ivermectin “is not meant to replace other COVID-19 measures such as social distancing, face masking and hygiene, or vaccinations,” adding that, “It is possibly an additional tool which can be deployed to fight the pandemic.”

The group stated that it has forwarded a report of its findings to NAFDAC.

Laolu Akande
Senior Special Assistant to the President on Media & Publicity

Support PREMIUM TIMES’ journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.
For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.
By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate


TEXT AD: To advertise here . Call Willie +2347088095401…






PT Mag Campaign AD




Source link

Facebook Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow Us
  • Contribute to MyNewsonPoint - Register to become an author to contribute with your knowledge.
  • Send breaking news, releases, photos or videos of happenings around the world Us via
Live Updates COVID-19 CASES
  • World 98,736,967
    World
    Confirmed: 98,736,967
    Active: 25,709,254
    Recovered: 70,911,554
    Death: 2,116,159
  • USA 25,390,042
    USA
    Confirmed: 25,390,042
    Active: 9,743,146
    Recovered: 15,222,719
    Death: 424,177
  • UK 3,583,907
    UK
    Confirmed: 3,583,907
    Active: 1,887,304
    Recovered: 1,600,622
    Death: 95,981
  • Italy 2,441,854
    Italy
    Confirmed: 2,441,854
    Active: 502,053
    Recovered: 1,855,127
    Death: 84,674
  • Nigeria 118,138
    Nigeria
    Confirmed: 118,138
    Active: 22,518
    Recovered: 94,130
    Death: 1,490
  • Ghana 59,480
    Ghana
    Confirmed: 59,480
    Active: 2,413
    Recovered: 56,706
    Death: 361
//stawhoph.com/afu.php?zoneid=3682068